Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTUV8G9)

• DTT Name: Progesterone receptor (PGR) DTT Info
• Gene Name: PGR

Molecule-Related Drug & Molecule List

12 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[1]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[2]
Ethynodiol Diacetate	DMZM84R	Contraception	QA21	Approved	[3]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[4]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[5]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[6]
Norethindrone	DMTY169	Acne vulgaris	ED80	Approved	[7]
Norgestimate	DMYP4XC	Acne vulgaris	ED80	Approved	[4]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[8]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[9]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[10]

11 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nestorone	DMVP7HI	Endometriosis	GA10	Phase 3	[11]
NPC-01	DMMC3Y8	Dysmenorrhea	GA34.3	Phase 3	[12]
BAY 86-5044	DMRZLU4	Breast cancer	2C60-2C65	Phase 2	[13]
MK-8342	DMD6E5W	Contraception	QA21	Phase 2	[14]
ONAPRISTONE	DMT6E5N	Breast cancer	2C60-2C65	Phase 2	[15]
S-PRAnt	DMFAO5G	Uterine fibroids	2E86.0	Phase 2	[16]
Telapristone	DM9AWSO	Endometriosis	GA10	Phase 2	[17]
Tosagestin	DM2HDTM	Contraception	QA21	Phase 2	[18]
Vilaprisan	DME7VZD	Endometriosis	GA10	Phase 2	[19]
Virexxa	DMEXMV5	Endometrial cancer	2C76	Phase 2	[14]
PF-2413873	DMCOUHT	Endometriosis	GA10	Phase 1	[20]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Asoprisnil	DM4BV2W	Endometriosis	GA10	Discontinued in Phase 3	[21]
Org-31710	DMZKTU5	Contraception	QA21	Discontinued in Phase 1	[22]
BAY-39-9624	DMPUG18	Osteoporosis	FB83.0	Terminated	[23]
RU-46556	DM8B1DH	Endometrial cancer	2C76	Terminated	[24]

25 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione	DMV7UC0	Discovery agent	N.A.	Investigative	[25]
2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline	DMP9ECK	Discovery agent	N.A.	Investigative	[26]
2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol	DMSHPCW	Discovery agent	N.A.	Investigative	[27]
3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one	DMUS0A4	Discovery agent	N.A.	Investigative	[28]
3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile	DMSHORK	Discovery agent	N.A.	Investigative	[29]
3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione	DMEG3YX	Discovery agent	N.A.	Investigative	[25]
4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile	DMBLAI1	Discovery agent	N.A.	Investigative	[30]
5,N-Dihydroxythalidomide	DM3MSZN	Discovery agent	N.A.	Investigative	[25]
5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile	DMR7OHB	Discovery agent	N.A.	Investigative	[29]
6-(3-Nitro-phenyl)-3H-benzothiazol-2-one	DM83VN6	Discovery agent	N.A.	Investigative	[31]
AL-43	DMLEDHR	Discovery agent	N.A.	Investigative	[32]
GSK-008A	DMC2ZF6	Gynecological disease	GA6Z	Investigative	[14]
GSK-1564023A	DMKN76P	Discovery agent	N.A.	Investigative	[33]
GSK-325971A	DM1865H	Discovery agent	N.A.	Investigative	[33]
GTPL8662	DMZQETV	Discovery agent	N.A.	Investigative	[34]
Lecanindole D	DMZ7OHP	Discovery agent	N.A.	Investigative	[35]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[36]
ORG2058	DMH1M6N	Discovery agent	N.A.	Investigative	[14]
PF-02367982	DMZ5JNT	Endometriosis	GA10	Investigative	[30]
Tanaproget	DMQCW7V	Estrogen deficiency	FB83.0Y	Investigative	[37]
WAY-255348	DMSLNWA	Solid tumour/cancer	2A00-2F9Z	Investigative	[29]
ZK-112993	DM8JN45	Discovery agent	N.A.	Investigative	[38]
ZK-114043	DMBCPKE	Discovery agent	N.A.	Investigative	[39]
ZK-136798	DMCQYBE	Discovery agent	N.A.	Investigative	[40]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[41]

References

• [1] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [2] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [3] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [4] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [5] Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24.
• [6] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [7] Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
• [8] Clinical pipeline report, company report or official report of lipocine.
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [11] Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97.
• [12] ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
• [13] Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
• [15] Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
• [16] BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64.
• [17] In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88.
• [18] Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939)
• [20] Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873. Journal of Labelled Compounds. 08/2009; 52(10):435 - 442.
• [21] New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
• [22] Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells. Fertil Steril. 2001 Dec;76(6):1225-31.
• [23] Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002.
• [24] New analogues of mifepristone with more dissociated antiprogesterone activities. J Steroid Biochem. 1989;34(1-6):413-7.
• [25] Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54.
• [26] Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem. 1998 Aug 27;41(18):3461-6.
• [27] Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):787-90.
• [28] 5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6666-9.
• [29] Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
• [30] Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6.
• [31] Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading... J Med Chem. 2005 Aug 11;48(16):5092-5.
• [32] Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
• [33] The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3.
• [34] A new strategy for selective targeting of progesterone receptor with passive antagonists. Mol Endocrinol. 2013 Jun;27(6):909-24.
• [35] The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. J Nat Prod. 2009 Nov;72(11):1944-8.
• [36] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [37] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [38] Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.Anticancer Res.1990 May-Jun;10(3):683-7.
• [39] Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998 Sep;158(3):401-7.
• [40] The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat. J Steroid Biochem Mol Biol. 1996 Sep;59(1):75-82.
• [41] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.